ameliaeve030
Member Since 25 Sep 2021Offline Last Active Sep 25 2021 10:42 AM
Community Stats
- Group User
- Active Posts 0
- Profile Views 822
- Time Online8m 41s
- Member Title Newbie
- Age 24 years old
- Birthday November 16, 1999
-
Gender
Male
-
Location
USA
-
Interests
Pharmacology: Pharmacodynamics: Mechanism of action: Ibrutinib is a potent, small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue (Cys-481) in the BTK active site, leading to sustained inhibition of BTK enzymatic activity. BTK, a member of the Tec kinase family, is an important signalling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. The BCR pathway is implicated in the pathogenesis of several B-cell malignancies, including MCL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and CLL. BTK's pivotal role in signalling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis and adhesion. Preclinical studies have shown that ibrutinib effectively inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.
Friends
ameliaeve030 hasn't added any friends yet.
Latest Visitors
No latest visitors to show